Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 23Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Leukemia 9Leukemia, Myeloid, Chronic-Phase 7Recurrence 4Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Congenital Abnormalities 1Blast Crisis 1

Interventions

Cyclophosphamide 72Cytarabine 61fludarabine phosphate 48venetoclax 42Peripheral Blood Stem Cell Transplantation 37fludarabine 34Busulfan 31Methotrexate 29Cyclosporine 29Mycophenolic Acid 28Filgrastim 27Azacitidine 27Antilymphocyte Serum 26Whole-Body Irradiation 22Etoposide 21Radiotherapy 20Melphalan 20Tacrolimus 19Rituximab 19Dexamethasone 16Methylprednisolone 15Granulocyte Colony-Stimulating Factor 15Decitabine 15Vincristine 14Cord Blood Stem Cell Transplantation 14Doxorubicin 13Clofarabine 11Mitoxantrone 10ibrutinib 9blinatumomab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recurrence × Homoharringtonine × Other hematologic neoplasm × Clear all
NCT04926285 2026-03-16

VEN-OM

University of Illinois at Chicago

Phase 1 Completed
6 enrolled
Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

NCT06742463 2024-12-19

VHAG in Treating R/R T-ALL/LBL

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
50 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05726110 2024-10-22

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Shanxi Bethune Hospital

Phase 3 Recruiting
50 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04722952 2021-12-03

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML

The First Affiliated Hospital of Soochow University

Phase 3 Unknown
30 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡